glp-1 competition

Novo Nordisk entered mid-June 2026 with its oral Wegovy expansion gathering regulatory and prescription momentum, Medicare coverage for eligible obesity patients due to begin on July 1, and a newly disclosed clinical-trial data breach weighing on an already battered share price. The investment...